1 | men | 30,140 |
2 | never-smokers | 112 |
3 | primigravidae | 92 |
4 | nulliparas | 40 |
5 | isografts | 23 |
6 | mddr | 18 |
7 | foreigners | 15 |
8 | camelids | 13 |
9 | picuristes | 12 |
10 | hiv-patients | 11 |
11 | nhws | 11 |
12 | saudis | 11 |
13 | russians | 10 |
14 | schoolboys | 10 |
15 | weightlifters | 10 |
16 | pmbcl | 9 |
17 | primi- | 9 |
18 | acromegalics | 8 |
19 | anurans | 8 |
20 | fgis | 8 |
21 | isdc | 8 |
22 | zpto | 8 |
23 | cvir | 7 |
24 | jvir | 7 |
25 | lumpectomies | 7 |
26 | ly1 | 7 |
27 | rsa1 | 7 |
28 | bjs | 6 |
29 | chf-lnmma | 6 |
30 | cpee | 6 |
31 | hypertriglyceridemics | 6 |
32 | jcog9205 | 6 |
33 | mddt | 6 |
34 | multigravidas | 6 |
35 | oklahomans | 6 |
36 | pashtuns | 6 |
37 | pcl-1 | 6 |
38 | air-bx1 | 5 |
39 | cdws | 5 |
40 | cholecysto-cholangiography | 5 |
41 | dyspeptics | 5 |
42 | fijians | 5 |
43 | gbac | 5 |
44 | hindus | 5 |
45 | o2/air | 5 |
46 | oncocytomas | 5 |
47 | sain | 5 |
48 | sfsws | 5 |
49 | 5th- | 4 |
50 | aquifolium | 4 |
51 | bullocks | 4 |
52 | intermediate-frail | 4 |
53 | mrc-only | 4 |
54 | obesses | 4 |
55 | peelings | 4 |
56 | pelf | 4 |
57 | souls | 4 |
58 | stims | 4 |
59 | 75-year-olds | 3 |
60 | bpi/lbp | 3 |
61 | children-adolescents | 3 |
62 | eunuchs | 3 |
63 | ex-offenders | 3 |
64 | mm.msec | 3 |
65 | ntpl | 3 |
66 | parkinsonians | 3 |
67 | pes- | 3 |
68 | pond-a | 3 |
69 | retroplast | 3 |
70 | ticagrelor- | 3 |
71 | zmhsp17.0-cii | 3 |
72 | 10-14-year-olds | 2 |
73 | 1996/97 | 2 |
74 | 2-5-year-olds | 2 |
75 | batswana | 2 |
76 | cheonan | 2 |
77 | coc-users | 2 |
78 | counter-rotational | 2 |
79 | dpsgc- | 2 |
80 | e/6 | 2 |
81 | g/child/day | 2 |
82 | hcms | 2 |
83 | isoalliin | 2 |
84 | kj/kg/day | 2 |
85 | mother- | 2 |
86 | non-vacuity | 2 |
87 | placebo.maternal | 2 |
88 | racewalkers | 2 |
89 | roxithromycine | 2 |
90 | sillenites | 2 |
91 | sopron | 2 |
92 | statin-users | 2 |
93 | undertrials | 2 |
94 | vegetables/fruit | 2 |
95 | +/-187 | 1 |
96 | +/-192 | 1 |
97 | +/-250 | 1 |
98 | +/-338 | 1 |
99 | +/-366 | 1 |
100 | .10m/sec | 1 |
101 | 1.0/nl | 1 |
102 | 100,000/mm3 | 1 |
103 | 100-nt | 1 |
104 | 102°f | 1 |
105 | 132/83 | 1 |
106 | 1966-73 | 1 |
107 | 20/500 | 1 |
108 | 20h/week | 1 |
109 | 23.60/30.10zzz | 1 |
110 | 2×/day | 1 |
111 | 4,003 | 1 |
112 | 4-hexylresorcinol | 1 |
113 | 42h | 1 |
114 | 55mmhg | 1 |
115 | 63,45 | 1 |
116 | 7mw | 1 |
117 | 928.9 | 1 |
118 | 94.50 | 1 |
119 | adolescences | 1 |
120 | antihistamine-treated | 1 |
121 | argentine- | 1 |
122 | asp/asn | 1 |
123 | atrcaα | 1 |
124 | border-case | 1 |
125 | brca2-carriers | 1 |
126 | chemotherapy-nai | 1 |
127 | comt_aa | 1 |
128 | cytology- | 1 |
129 | emotional/mental- | 1 |
130 | enr2 | 1 |
131 | erythritol- | 1 |
132 | eswls | 1 |
133 | etravirine- | 1 |
134 | eunoctin | 1 |
135 | fever/infections | 1 |
136 | formoterol-randomized | 1 |
137 | fsbs | 1 |
138 | gst-vaccinated | 1 |
139 | hispanic-americans | 1 |
140 | hpa/pku | 1 |
141 | hu/pixel | 1 |
142 | hypospadics | 1 |
143 | ibu200 | 1 |
144 | ileostomy/jejunostomy | 1 |
145 | imams | 1 |
146 | imipenem/cilsatatin | 1 |
147 | intervention-patients | 1 |
148 | ivapap | 1 |
149 | kg/height2 | 1 |
150 | l21p | 1 |
151 | lepidosiren | 1 |
152 | lesogaberan- | 1 |
153 | live- | 1 |
154 | lnfgf-23 | 1 |
155 | minor–peer | 1 |
156 | mortaliity | 1 |
157 | multivented | 1 |
158 | n-hdl3 | 1 |
159 | nonbridgers | 1 |
160 | noncoached | 1 |
161 | nongynecology | 1 |
162 | nonsingletons | 1 |
163 | not-transfected | 1 |
164 | oah-exposed | 1 |
165 | own-price | 1 |
166 | panitumumab+folfiri | 1 |
167 | panitumumab+folfox4 | 1 |
168 | pet28a-lipab | 1 |
169 | phenylethoxy | 1 |
170 | pimeloyl-coa | 1 |
171 | pre-media | 1 |
172 | pregabalin- | 1 |
173 | proportions=-0.0110 | 1 |
174 | proportions=-0.0170 | 1 |
175 | proportions=0.0020 | 1 |
176 | proportions=0.0130 | 1 |
177 | remission=0.64 | 1 |
178 | remission=0.85 | 1 |
179 | scleroderma-controls | 1 |
180 | sedentaries | 1 |
181 | sporstmen | 1 |
182 | tables/graphs | 1 |
183 | tnm1 | 1 |
184 | trpml2 | 1 |
185 | vhl-1 | 1 |
186 | wexford | 1 |
187 | who- | 1 |
188 | ¿m | 1 |
189 | δl=0.36 | 1 |
1 | +/-187 | 1 |
2 | +/-192 | 1 |
3 | +/-250 | 1 |
4 | +/-338 | 1 |
5 | +/-366 | 1 |
6 | .10m/sec | 1 |
7 | 1.0/nl | 1 |
8 | 10-14-year-olds | 2 |
9 | 100,000/mm3 | 1 |
10 | 100-nt | 1 |
11 | 102°f | 1 |
12 | 132/83 | 1 |
13 | 1966-73 | 1 |
14 | 1996/97 | 2 |
15 | 2-5-year-olds | 2 |
16 | 20/500 | 1 |
17 | 20h/week | 1 |
18 | 23.60/30.10zzz | 1 |
19 | 2×/day | 1 |
20 | 4,003 | 1 |
21 | 4-hexylresorcinol | 1 |
22 | 42h | 1 |
23 | 55mmhg | 1 |
24 | 5th- | 4 |
25 | 63,45 | 1 |
26 | 75-year-olds | 3 |
27 | 7mw | 1 |
28 | 928.9 | 1 |
29 | 94.50 | 1 |
30 | acromegalics | 8 |
31 | adolescences | 1 |
32 | air-bx1 | 5 |
33 | antihistamine-treated | 1 |
34 | anurans | 8 |
35 | aquifolium | 4 |
36 | argentine- | 1 |
37 | asp/asn | 1 |
38 | atrcaα | 1 |
39 | batswana | 2 |
40 | bjs | 6 |
41 | border-case | 1 |
42 | bpi/lbp | 3 |
43 | brca2-carriers | 1 |
44 | bullocks | 4 |
45 | camelids | 13 |
46 | cdws | 5 |
47 | chemotherapy-nai | 1 |
48 | cheonan | 2 |
49 | chf-lnmma | 6 |
50 | children-adolescents | 3 |
51 | cholecysto-cholangiography | 5 |
52 | coc-users | 2 |
53 | comt_aa | 1 |
54 | counter-rotational | 2 |
55 | cpee | 6 |
56 | cvir | 7 |
57 | cytology- | 1 |
58 | dpsgc- | 2 |
59 | dyspeptics | 5 |
60 | e/6 | 2 |
61 | emotional/mental- | 1 |
62 | enr2 | 1 |
63 | erythritol- | 1 |
64 | eswls | 1 |
65 | etravirine- | 1 |
66 | eunoctin | 1 |
67 | eunuchs | 3 |
68 | ex-offenders | 3 |
69 | fever/infections | 1 |
70 | fgis | 8 |
71 | fijians | 5 |
72 | foreigners | 15 |
73 | formoterol-randomized | 1 |
74 | fsbs | 1 |
75 | g/child/day | 2 |
76 | gbac | 5 |
77 | gst-vaccinated | 1 |
78 | hcms | 2 |
79 | hindus | 5 |
80 | hispanic-americans | 1 |
81 | hiv-patients | 11 |
82 | hpa/pku | 1 |
83 | hu/pixel | 1 |
84 | hypertriglyceridemics | 6 |
85 | hypospadics | 1 |
86 | ibu200 | 1 |
87 | ileostomy/jejunostomy | 1 |
88 | imams | 1 |
89 | imipenem/cilsatatin | 1 |
90 | intermediate-frail | 4 |
91 | intervention-patients | 1 |
92 | isdc | 8 |
93 | isoalliin | 2 |
94 | isografts | 23 |
95 | ivapap | 1 |
96 | jcog9205 | 6 |
97 | jvir | 7 |
98 | kg/height2 | 1 |
99 | kj/kg/day | 2 |
100 | l21p | 1 |
101 | lepidosiren | 1 |
102 | lesogaberan- | 1 |
103 | live- | 1 |
104 | lnfgf-23 | 1 |
105 | lumpectomies | 7 |
106 | ly1 | 7 |
107 | mddr | 18 |
108 | mddt | 6 |
109 | men | 30,140 |
110 | minor–peer | 1 |
111 | mm.msec | 3 |
112 | mortaliity | 1 |
113 | mother- | 2 |
114 | mrc-only | 4 |
115 | multigravidas | 6 |
116 | multivented | 1 |
117 | n-hdl3 | 1 |
118 | never-smokers | 112 |
119 | nhws | 11 |
120 | non-vacuity | 2 |
121 | nonbridgers | 1 |
122 | noncoached | 1 |
123 | nongynecology | 1 |
124 | nonsingletons | 1 |
125 | not-transfected | 1 |
126 | ntpl | 3 |
127 | nulliparas | 40 |
128 | o2/air | 5 |
129 | oah-exposed | 1 |
130 | obesses | 4 |
131 | oklahomans | 6 |
132 | oncocytomas | 5 |
133 | own-price | 1 |
134 | panitumumab+folfiri | 1 |
135 | panitumumab+folfox4 | 1 |
136 | parkinsonians | 3 |
137 | pashtuns | 6 |
138 | pcl-1 | 6 |
139 | peelings | 4 |
140 | pelf | 4 |
141 | pes- | 3 |
142 | pet28a-lipab | 1 |
143 | phenylethoxy | 1 |
144 | picuristes | 12 |
145 | pimeloyl-coa | 1 |
146 | placebo.maternal | 2 |
147 | pmbcl | 9 |
148 | pond-a | 3 |
149 | pre-media | 1 |
150 | pregabalin- | 1 |
151 | primi- | 9 |
152 | primigravidae | 92 |
153 | proportions=-0.0110 | 1 |
154 | proportions=-0.0170 | 1 |
155 | proportions=0.0020 | 1 |
156 | proportions=0.0130 | 1 |
157 | racewalkers | 2 |
158 | remission=0.64 | 1 |
159 | remission=0.85 | 1 |
160 | retroplast | 3 |
161 | roxithromycine | 2 |
162 | rsa1 | 7 |
163 | russians | 10 |
164 | sain | 5 |
165 | saudis | 11 |
166 | schoolboys | 10 |
167 | scleroderma-controls | 1 |
168 | sedentaries | 1 |
169 | sfsws | 5 |
170 | sillenites | 2 |
171 | sopron | 2 |
172 | souls | 4 |
173 | sporstmen | 1 |
174 | statin-users | 2 |
175 | stims | 4 |
176 | tables/graphs | 1 |
177 | ticagrelor- | 3 |
178 | tnm1 | 1 |
179 | trpml2 | 1 |
180 | undertrials | 2 |
181 | vegetables/fruit | 2 |
182 | vhl-1 | 1 |
183 | weightlifters | 10 |
184 | wexford | 1 |
185 | who- | 1 |
186 | zmhsp17.0-cii | 3 |
187 | zpto | 8 |
188 | ¿m | 1 |
189 | δl=0.36 | 1 |
1 | dpsgc- | 2 |
2 | etravirine- | 1 |
3 | argentine- | 1 |
4 | live- | 1 |
5 | 5th- | 4 |
6 | primi- | 9 |
7 | emotional/mental- | 1 |
8 | erythritol- | 1 |
9 | lesogaberan- | 1 |
10 | pregabalin- | 1 |
11 | who- | 1 |
12 | mother- | 2 |
13 | ticagrelor- | 3 |
14 | pes- | 3 |
15 | cytology- | 1 |
16 | ibu200 | 1 |
17 | 20/500 | 1 |
18 | proportions=-0.0110 | 1 |
19 | proportions=0.0020 | 1 |
20 | proportions=0.0130 | 1 |
21 | 94.50 | 1 |
22 | +/-250 | 1 |
23 | proportions=-0.0170 | 1 |
24 | pcl-1 | 6 |
25 | vhl-1 | 1 |
26 | rsa1 | 7 |
27 | tnm1 | 1 |
28 | air-bx1 | 5 |
29 | ly1 | 7 |
30 | +/-192 | 1 |
31 | trpml2 | 1 |
32 | enr2 | 1 |
33 | kg/height2 | 1 |
34 | 4,003 | 1 |
35 | lnfgf-23 | 1 |
36 | 1966-73 | 1 |
37 | 132/83 | 1 |
38 | n-hdl3 | 1 |
39 | 100,000/mm3 | 1 |
40 | remission=0.64 | 1 |
41 | panitumumab+folfox4 | 1 |
42 | jcog9205 | 6 |
43 | 63,45 | 1 |
44 | remission=0.85 | 1 |
45 | e/6 | 2 |
46 | δl=0.36 | 1 |
47 | +/-366 | 1 |
48 | +/-187 | 1 |
49 | 1996/97 | 2 |
50 | +/-338 | 1 |
51 | 928.9 | 1 |
52 | pond-a | 3 |
53 | comt_aa | 1 |
54 | pre-media | 1 |
55 | chf-lnmma | 6 |
56 | batswana | 2 |
57 | pimeloyl-coa | 1 |
58 | pet28a-lipab | 1 |
59 | gbac | 5 |
60 | isdc | 8 |
61 | .10m/sec | 1 |
62 | mm.msec | 3 |
63 | noncoached | 1 |
64 | oah-exposed | 1 |
65 | antihistamine-treated | 1 |
66 | gst-vaccinated | 1 |
67 | not-transfected | 1 |
68 | multivented | 1 |
69 | formoterol-randomized | 1 |
70 | wexford | 1 |
71 | primigravidae | 92 |
72 | own-price | 1 |
73 | cpee | 6 |
74 | roxithromycine | 2 |
75 | border-case | 1 |
76 | pelf | 4 |
77 | 102°f | 1 |
78 | 55mmhg | 1 |
79 | 42h | 1 |
80 | chemotherapy-nai | 1 |
81 | zmhsp17.0-cii | 3 |
82 | panitumumab+folfiri | 1 |
83 | 20h/week | 1 |
84 | counter-rotational | 2 |
85 | placebo.maternal | 2 |
86 | pmbcl | 9 |
87 | hu/pixel | 1 |
88 | intermediate-frail | 4 |
89 | 1.0/nl | 1 |
90 | 4-hexylresorcinol | 1 |
91 | ntpl | 3 |
92 | aquifolium | 4 |
93 | ¿m | 1 |
94 | cheonan | 2 |
95 | men | 30,140 |
96 | sporstmen | 1 |
97 | lepidosiren | 1 |
98 | sain | 5 |
99 | isoalliin | 2 |
100 | imipenem/cilsatatin | 1 |
101 | eunoctin | 1 |
102 | sopron | 2 |
103 | asp/asn | 1 |
104 | zpto | 8 |
105 | l21p | 1 |
106 | ivapap | 1 |
107 | bpi/lbp | 3 |
108 | mddr | 18 |
109 | minor–peer | 1 |
110 | o2/air | 5 |
111 | cvir | 7 |
112 | jvir | 7 |
113 | multigravidas | 6 |
114 | oncocytomas | 5 |
115 | nulliparas | 40 |
116 | fsbs | 1 |
117 | hypospadics | 1 |
118 | acromegalics | 8 |
119 | hypertriglyceridemics | 6 |
120 | dyspeptics | 5 |
121 | camelids | 13 |
122 | 10-14-year-olds | 2 |
123 | 2-5-year-olds | 2 |
124 | 75-year-olds | 3 |
125 | adolescences | 1 |
126 | lumpectomies | 7 |
127 | sedentaries | 1 |
128 | obesses | 4 |
129 | sillenites | 2 |
130 | picuristes | 12 |
131 | peelings | 4 |
132 | eunuchs | 3 |
133 | tables/graphs | 1 |
134 | saudis | 11 |
135 | fgis | 8 |
136 | bjs | 6 |
137 | bullocks | 4 |
138 | undertrials | 2 |
139 | scleroderma-controls | 1 |
140 | souls | 4 |
141 | eswls | 1 |
142 | imams | 1 |
143 | hcms | 2 |
144 | stims | 4 |
145 | hispanic-americans | 1 |
146 | fijians | 5 |
147 | parkinsonians | 3 |
148 | russians | 10 |
149 | oklahomans | 6 |
150 | anurans | 8 |
151 | fever/infections | 1 |
152 | nonsingletons | 1 |
153 | pashtuns | 6 |
154 | ex-offenders | 3 |
155 | nonbridgers | 1 |
156 | brca2-carriers | 1 |
157 | racewalkers | 2 |
158 | never-smokers | 112 |
159 | foreigners | 15 |
160 | coc-users | 2 |
161 | statin-users | 2 |
162 | weightlifters | 10 |
163 | isografts | 23 |
164 | children-adolescents | 3 |
165 | intervention-patients | 1 |
166 | hiv-patients | 11 |
167 | hindus | 5 |
168 | cdws | 5 |
169 | nhws | 11 |
170 | sfsws | 5 |
171 | schoolboys | 10 |
172 | mddt | 6 |
173 | vegetables/fruit | 2 |
174 | 100-nt | 1 |
175 | retroplast | 3 |
176 | hpa/pku | 1 |
177 | 7mw | 1 |
178 | g/child/day | 2 |
179 | kj/kg/day | 2 |
180 | 2×/day | 1 |
181 | nongynecology | 1 |
182 | cholecysto-cholangiography | 5 |
183 | mrc-only | 4 |
184 | ileostomy/jejunostomy | 1 |
185 | mortaliity | 1 |
186 | non-vacuity | 2 |
187 | phenylethoxy | 1 |
188 | 23.60/30.10zzz | 1 |
189 | atrcaα | 1 |